Drug-eluting stent thrombosis

Minerva Cardioangiologica

Volumn 57, Issue 5, 2009, Pages 611-620

  Pilgrim, T ^a   Windecker, S ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Drug eluting stents; Mortality; Thrombosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; BIOLIMUS A9; ENDEAVOR; EVEROLIMUS; PACLITAXEL; POLYMER; RAPAMYCIN; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; AGE; ARTERY CALCIFICATION; ARTERY DIAMETER; BARE METAL STENT; CARDIOVASCULAR RISK; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY RECANALIZATION; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DEVICE THERAPY; DRUG ELUTING STENT; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MORTALITY; NEOPLASM; REVIEW; STENT THROMBOSIS; WOUND HEALING IMPAIRMENT; ARTICLE; PATHOPHYSIOLOGY; PROSTHESIS; RISK FACTOR; THROMBOSIS;

DRUG-ELUTING STENTS; HUMANS; PROSTHESIS DESIGN; RISK FACTORS; THROMBOSIS;

EID: 77449090893     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Bittl JA. Advances in coronary angioplasty. N Engl J Med 1996;335:1290-302.
2. Windecker S, Meier B. Intervention in coronary artery disease. Heart 2000;83:481-90.
3. Detre K, Holubkov R, Kelsey S, Bourassa M, Williams D, Holmes D Jr et al. One-year follow-up results of the 1985-1986 National Heart, Lung, and Blood Institute's Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1989;80:421-8.
4. Roubin GS, Cannon AD, Agrawal SK, Macander PJ, Dean LS, Baxley WA et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992;85:916-27.
5. Schömig A, Kastrati A, Mudra H, Blasini R, Schühlen H, Klauss V et al. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. Circulation 1994;90:2716-24.
6. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med 2003;138:777-86.
7. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23-
8. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
9. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med 2006;354:483-95.
10. Stealer C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-48.
11. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78.
12. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-61.
13. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
14. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9.
15. Windecker S, Meier B. Late coronary stent thrombosis. Circulation 2007;116:1952-65.
16. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
17. Stone GW, Ellis SG, Colombo A, Dawkins KD, Grube E, Cutlip DE et al. Offsetting impart of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation 2007;115:2842-7.
18. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-71.
19. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006;113:1108-13.
20. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
21. Rodriguez AE, Mieres J, Fernandez-Pereira C, Vigo CF, Rodriguez-Alemparte M, Berrocal D et al. Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III trial. J Am Coll Cardiol 2006;47:205-7.
22. Park DW, Park SW, Lee SW, Kim YH, Lee CW, Hong MK et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006;98:352-6.
23. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;45:947-53.
24. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). Am J Cardiol 2005;95:1469-72.
25. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J Am Coll Cardiol 2005;45: 941-6.
26. Moreno R, Fernández C, Hernández R, Alfonso F, Angiolillo DJ, Sabaté M et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-9.
27. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005;293:165-71.
28. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Jüni P, Vaina S et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008;52:1134-40.
29. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-9.
30. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009;119:3198-206.
31. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
32. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-5.
33. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435-41.
34. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006;47:2108-11.
35. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005;46:231-6.
36. Togni M, Räber L, Cocchia R, Wenaweser P, Cook S, Windecker S et al. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol 2007;120:212-20. (Pubitemid 47042255)
37. Feres F, Costa JR, Abizaid A. Very late thrombosis after drug-eluting stents. Catheter Cardiovasc Interv 2006;68:83-8. (Pubitemid 44024467)
38. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007;115:2426-34. (Pubitemid 46717965)
39. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-81.
40. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009;120:391-9.
41. Steffel J, Latini RA, Akhmedov A, Zimmermann D, Zimmerling P, Lüscher TF et al. Rapamycin, but not FK-506, increases endothelial tissue Factor expression: implications for drug-eluting stent design. Circulation 2005;112:2002-11. (Pubitemid 41377420)
42. Stählt BE, Camici GG, Steffel J, Akhmedov A, Shojaati K, Graber M et al. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res 2006;99:149-55. (Pubitemid 44297038)
43. Biondi-Zoccai GG, Agostoni P, Sangiorgi GM, Airoldi F, Cosgrave J, Chieffo A et al. Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantation. Eur Heart J 2006;27:540-6.
44. Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 2005;45:995-8. (Pubitemid 40432428)
45. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006;113:1434-41. (Pubitemid 43739440)
46. van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009;53:1399-409.
47. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849-56.
48. Wenaweser P, Hess O. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;45:1748-52. (Pubitemid 40779850)
49. Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745-54.
50. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009;119:987-95.
51. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verfleugt FW et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
52. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903-13. (Pubitemid 351574920)
53. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two year clinical follow-up from the SPIRIT III trial. Circulation, 2008. in press.
54. Windecker, S. and P. Juni, The drug-eluting stent saga. Circulation 2009;119:680-6.
55. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114:798-806. (Pubitemid 44268230)
56. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008;372:1163-73.
57. Hamilos MI, Ostojic M, Beleslin B, Sagic D, Mangovski L, Stojkovic S et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 2008;51:2123-9. (Pubitemid 351721001)